DE69703689T2 - Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia - Google Patents

Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia

Info

Publication number
DE69703689T2
DE69703689T2 DE69703689T DE69703689T DE69703689T2 DE 69703689 T2 DE69703689 T2 DE 69703689T2 DE 69703689 T DE69703689 T DE 69703689T DE 69703689 T DE69703689 T DE 69703689T DE 69703689 T2 DE69703689 T2 DE 69703689T2
Authority
DE
Germany
Prior art keywords
meningococcämia
protein products
bpi protein
therapeutic applications
treating human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69703689T
Other languages
English (en)
Other versions
DE69703689D1 (de
Inventor
P Giroir
J Scannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Technology Ltd USA
Original Assignee
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd USA filed Critical Xoma Technology Ltd USA
Application granted granted Critical
Publication of DE69703689D1 publication Critical patent/DE69703689D1/de
Publication of DE69703689T2 publication Critical patent/DE69703689T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69703689T 1996-05-10 1997-05-09 Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia Expired - Fee Related DE69703689T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64428796A 1996-05-10 1996-05-10
PCT/US1997/008016 WO1997042966A1 (en) 1996-05-10 1997-05-09 Therapeutic uses of bpi protein products for human meningococcemia

Publications (2)

Publication Number Publication Date
DE69703689D1 DE69703689D1 (de) 2001-01-18
DE69703689T2 true DE69703689T2 (de) 2001-05-10

Family

ID=24584256

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69703689T Expired - Fee Related DE69703689T2 (de) 1996-05-10 1997-05-09 Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia

Country Status (15)

Country Link
US (4) US5888977A (de)
EP (1) EP0914144B1 (de)
JP (1) JP2000510845A (de)
CN (1) CN1236320A (de)
AT (1) ATE198050T1 (de)
AU (1) AU735058B2 (de)
CA (1) CA2253837C (de)
DE (1) DE69703689T2 (de)
DK (1) DK0914144T3 (de)
ES (1) ES2153665T3 (de)
GR (1) GR3035440T3 (de)
HK (1) HK1019856A1 (de)
NZ (2) NZ332720A (de)
PT (1) PT914144E (de)
WO (1) WO1997042966A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6214789B1 (en) * 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6464700B1 (en) 1994-10-07 2002-10-15 Scimed Life Systems, Inc. Loop structures for positioning a diagnostic or therapeutic element on the epicardium or other organ surface
US6071274A (en) * 1996-12-19 2000-06-06 Ep Technologies, Inc. Loop structures for supporting multiple electrode elements
CA2227292A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
ATE198050T1 (de) * 1996-05-10 2000-12-15 Xoma Technology Ltd Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6048329A (en) 1996-12-19 2000-04-11 Ep Technologies, Inc. Catheter distal assembly with pull wires
US6203525B1 (en) 1996-12-19 2001-03-20 Ep Technologies, Inc. Catheterdistal assembly with pull wires
US6071279A (en) * 1996-12-19 2000-06-06 Ep Technologies, Inc. Branched structures for supporting multiple electrode elements
US6332880B1 (en) 1996-12-19 2001-12-25 Ep Technologies, Inc. Loop structures for supporting multiple electrode elements
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6610055B1 (en) 1997-10-10 2003-08-26 Scimed Life Systems, Inc. Surgical method for positioning a diagnostic or therapeutic element on the epicardium or other organ surface
NZ532665A (en) * 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
NZ513087A (en) * 1999-01-22 2003-02-28 Xoma Technology Ltd Bactericidal/permability -increasing protein (BPI) for treating chronic heart disease
US6217528B1 (en) 1999-02-11 2001-04-17 Scimed Life Systems, Inc. Loop structure having improved tissue contact capability
US6529756B1 (en) 1999-11-22 2003-03-04 Scimed Life Systems, Inc. Apparatus for mapping and coagulating soft tissue in or around body orifices
US6645199B1 (en) 1999-11-22 2003-11-11 Scimed Life Systems, Inc. Loop structures for supporting diagnostic and therapeutic elements contact with body tissue and expandable push devices for use with same
US6542781B1 (en) 1999-11-22 2003-04-01 Scimed Life Systems, Inc. Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue
US6613046B1 (en) 1999-11-22 2003-09-02 Scimed Life Systems, Inc. Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue
AU2001255339A1 (en) * 2000-04-14 2001-10-30 Biotime, Inc. Systems, kits, and methods of administering synthetic plasma
CA2430588A1 (en) * 2000-12-01 2002-07-18 Xoma Technology Ltd. Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
EP1741440A1 (de) 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
US20090259171A1 (en) * 2008-04-09 2009-10-15 Joshi Ashok V Transdermal Oxygen-Delivery Apparatus and Method
DE102010015682B4 (de) 2010-04-21 2014-01-02 Peter Arnold Vorrichtung zum Erfassen der Prozessstrahlung bei der Lasermaterialbearbeitung
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245013A (en) * 1985-04-30 1993-09-14 Richard Ulevitch Acute phase protein modulating endotoxic activity of lipopolysaccharides, assay methods and polypeptides
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
AU645515B2 (en) * 1989-08-01 1994-01-20 Rockefeller University, The Methods and compositions for ameliorating the symptoms of sepsis
AU9127591A (en) * 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
JPH07502642A (ja) * 1991-09-26 1995-03-23 インサイト　ファーマシューティカルズ，インコーポレイテッド 新規な形態のリポ糖結合性タンパク質（ｌｂｐ）
WO1993023540A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
CN1163264C (zh) * 1993-02-02 2004-08-25 爱克索马技术有限公司 改进的药物组合物
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
ATE165976T1 (de) * 1993-03-12 1998-05-15 Xoma Corp Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
JPH08509703A (ja) * 1993-03-12 1996-10-15 ゾーマ コーポレイション 殺菌／透過性増加タンパク質産物の治療用途
DK0690872T3 (da) * 1993-03-12 1999-05-10 Xoma Corp Biologisk aktive peptider fra funktionelle domæner af baktericidt/permeabilitetsforøgende protein og anvendelser deraf
WO1994021280A1 (en) * 1993-03-22 1994-09-29 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis
AU6942994A (en) * 1993-04-30 1994-11-21 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
AU7175694A (en) * 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
WO1995001428A1 (en) * 1993-07-02 1995-01-12 Incyte Pharmaceuticals, Inc. Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
AU7330994A (en) * 1993-07-14 1995-02-13 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5466580A (en) * 1993-09-22 1995-11-14 Xoma Corporation Method for quantifying BPI in body fluids
CA2172245C (en) * 1993-09-22 2003-04-08 Jonathan Cohen Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
EP0722333B1 (de) * 1993-10-05 2004-06-16 XOMA Technology Ltd. Bpi-protein-produkte für definierte funktionen des reticuloendothelialen systems
JPH09508357A (ja) * 1994-01-14 1997-08-26 ゾーマ コーポレイション 抗真菌方法及び材料
EP0754050B1 (de) * 1994-01-14 2002-06-26 XOMA Technology Ltd. Anti gram positive bakterielle verfahren und mittel
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
AU709738B2 (en) * 1994-09-15 1999-09-02 Xoma Corporation Anti-fungal peptides
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
ATE198050T1 (de) * 1996-05-10 2000-12-15 Xoma Technology Ltd Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
GB2316940A (en) 1996-08-30 1998-03-11 Queen Mary & Westfield College Silicon-substituted hydroxyapatite

Also Published As

Publication number Publication date
HK1019856A1 (en) 2000-03-03
US5990086A (en) 1999-11-23
US6596691B2 (en) 2003-07-22
US5888977A (en) 1999-03-30
EP0914144A1 (de) 1999-05-12
AU735058B2 (en) 2001-06-28
CN1236320A (zh) 1999-11-24
ATE198050T1 (de) 2000-12-15
CA2253837A1 (en) 1997-11-20
NZ332720A (en) 2000-07-28
EP0914144B1 (de) 2000-12-13
DE69703689D1 (de) 2001-01-18
JP2000510845A (ja) 2000-08-22
US20020103114A1 (en) 2002-08-01
PT914144E (pt) 2001-05-31
WO1997042966A1 (en) 1997-11-20
ES2153665T3 (es) 2001-03-01
DK0914144T3 (da) 2001-04-09
US6242418B1 (en) 2001-06-05
GR3035440T3 (en) 2001-05-31
CA2253837C (en) 2002-07-02
NZ505070A (en) 2005-01-28
AU3004397A (en) 1997-12-05

Similar Documents

Publication Publication Date Title
DE69703689T2 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE69718150T2 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
DE69535673D1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
DE69631381T2 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE69822276T2 (de) Kräuter formulierung mit therapeutischer und kosmetischer verwendung zur behandlung von allgemeinen hauterkrankungen
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69231465T2 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
DE69430807T2 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
DE9411818U1 (de) Medizinisches Gerät zur Behandlung von rheumatischen Schmerzen
DE29803925U1 (de) Radial-Belüfter zur Behandlung von Wunden und Hauterkrankungen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: XOMA TECHNOLOGY LTD., BERKELEY, CALIF., US BOARD O

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee